Vanda Pharma Misses Q1 Revenue Estimates, Lifts 2026 Outlook to $240-$290M on Nereus Launch
VNDA sits 90% above its 52-week low of $3.809.
Summary
Vanda Pharmaceuticals reported a Q1 revenue miss, coming in at $51.72 million against analyst estimates of $54.98 million, alongside a net loss of $48.57 million. Despite the quarterly shortfall, the company significantly raised its full-year 2026 revenue guidance to a range of $240-$290 million. This upward revision is primarily driven by the recent U.S. commercial launch of Nereus (tradipitant) for motion sickness, which was announced on May 1st and is now expected to contribute $10-$30 million in net product sales for 2026. While the Q1 miss is a negative, the substantial increase in full-year guidance, fueled by a new product, provides a strong positive outlook for future growth and could be a significant catalyst for the stock. Traders will be closely watching the Nereus sales trajectory and the upcoming FDA decision for imsidolimab in December 2026.
At the time of this announcement, VNDA was trading at $7.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $439.8M. The 52-week trading range was $3.81 to $9.94. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.